Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.

Conclusions: Despite routine use of alemtuzumab, clinical presentations of AITD seem to be uncommon in CIT patients receiving immunosuppression. However, AITD can develop following withdrawal of immunosuppression, highlighting the need for careful thyroid surveillance in this population.
PMID: 30398662 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - November 5, 2018 Category: Endocrinology Authors: Dunn A, Lam A, Hidalgo L, Shapiro AJ, Senior PA Tags: J Clin Endocrinol Metab Source Type: research